ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Prognostic significance of DNA ploidy, stroma fraction, and nucleotyping in stage IIIb colon cancer and their implications for adjuvant chemotherapy.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SFTA2 reduced colorectal cancer ferroptosis promoting metastasis through regulating EMT transition by degradation of Nrf2.Food & nutrition research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDNA ploidy (P), stroma fraction (S), and nucleotyping (N), collectively known as PSN, have demonstrated prognostic accuracy in various stages of colorectal cancer (CRC). However, the prognostic value of the PSN panel in stage IIIb colon cancer patients receiving CapOX adjuvant chemotherapy remains unclear. PATIENTS AND
methodsPostoperative pathological samples from stage IIIb colon cancer patients who underwent radical surgery and postoperative adjuvant chemotherapy at Sun Yat-sen University Cancer Center were retrospectively collected. Kaplan-Meier and Cox regression were performed to compare survival among subgroups of patients stratified by PSN, in order to elucidate the benefits of different durations of adjuvant CapOX chemotherapy.
resultThe PSN low-risk group had the highest 5-year DFS (95.77% vs. 83.07% vs. 84.29%, P = 0.023). Multivariate Cox regression analysis identified primary tumor location (HR = 4.166, 95% CI 1.616-10.742, P = 0.003), perineural invasion (HR = 2.358, 95% CI 1.205-4.615, P = 0.012), and PSN high risk (HR = 3.830, 95% CI 1.352-10.853, P = 0.011) as independent predictors of DFS. No significant difference in 5-year DFS and overall survival (OS) was observed between patients receiving 4-7 cycles and those receiving 8 cycles of CapOX (DFS: 86.24% vs. 88.77%, P = 0.082; OS: 96.38% vs. 94.23%, P = 0.088). However, in the PSN high-risk group, completing 8 cycles of CapOX significantly improved 5-year DFS and OS compared to 4-7 cycles (DFS: 93.10% vs. 77.04%, P = 0.033; OS: 96.30% vs. 91.24%, P = 0.037). In contrast, no significant difference in DFS was observed in the IDEA (International Duration Evaluation of Adjuvant therapy)-based high-risk group (DFS: 85.85% vs. 80.75%, P = 0.062; OS: 97.56% vs. 87.05%, P = 0.598).
conclusionThe PSN panel effectively stratifies stage IIIb colon cancer, aiding in optimized adjuvant chemotherapy duration determination.
Indexed as
Identifiers
40841502What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.